The Marked Chart Wire · Business
Pharming
Pharming posts 21 percent revenue jump in third quarter, narrows 2026 outlook
Pharming reported third-quarter sales of $117.6 million, a 21 percent increase from last year, with operating costs at $74.6 million. The firm cut its 2026 revenue forecast to $380 million to $390 million and plans to finish its Napazimone trial enrollment by mid-2027.
